DJ-1 based peptide, ND-13, promote functional recovery in mouse model of focal ischemic injury

PLoS One. 2018 Feb 28;13(2):e0192954. doi: 10.1371/journal.pone.0192954. eCollection 2018.

Abstract

Stroke is a leading cause of death worldwide and inflicts serious long-term damage and disability. The vasoconstrictor Endothelin-1, presenting long-term neurological deficits associated with excitotoxicity and oxidative stress is being increasingly used to induce focal ischemic injury as a model of stroke. A DJ-1 based peptide named ND-13 was shown to protect against glutamate toxicity, neurotoxic insults and oxidative stress in various animal models. Here we focus on the benefits of treatment with ND-13 on the functional outcome of focal ischemic injury. Wild type C57BL/6 mice treated with ND-13, after ischemic induction in this model, showed significant improvement in motor function, including improved body balance and motor coordination, and decreased motor asymmetry. We found that DJ-1 knockout mice are more sensitive to Endothelin-1 ischemic insult than wild type mice, contributing thereby additional evidence to the widely reported relevance of DJ-1 in neuroprotection. Furthermore, treatment of DJ-1 knockout mice with ND-13, following Endothelin-1 induced ischemia, resulted in significant improvement in motor functions, suggesting that ND-13 provides compensation for DJ-1 deficits. These preliminary results demonstrate a possible basis for clinical application of the ND-13 peptide to enhance neuroprotection in stroke patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / etiology
  • Brain Ischemia / physiopathology
  • Cell-Penetrating Peptides / genetics
  • Cell-Penetrating Peptides / therapeutic use
  • Disease Models, Animal
  • Endothelin-1 / toxicity
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neuroprotective Agents / therapeutic use
  • Oxidative Stress / drug effects
  • Peptide Fragments / genetics
  • Peptide Fragments / therapeutic use*
  • Protein Deglycase DJ-1 / deficiency
  • Protein Deglycase DJ-1 / genetics
  • Protein Deglycase DJ-1 / therapeutic use*
  • Recovery of Function / drug effects
  • Stroke / drug therapy
  • Stroke / etiology
  • Stroke / physiopathology
  • Vasoconstrictor Agents / toxicity

Substances

  • Cell-Penetrating Peptides
  • DJ-1 based peptide, ND-13
  • Endothelin-1
  • Neuroprotective Agents
  • Peptide Fragments
  • Vasoconstrictor Agents
  • Protein Deglycase DJ-1

Grants and funding

UGH Pharma, Inc. supplied the peptide (ND-13) used in the studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.